secwatch.observer — SEC 8-K summary
======================================

Issuer:     GALECTIN THERAPEUTICS INC (GALT)
CIK:        0001133416
Form:       8-K
Filed at:   2026-08-14T11:55:46+00:00
Accession:  0001140361-26-032946
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galectin reports Q2 net loss $9.2M; FDA agrees on Phase 3 design for belapectin
-------------------------------------------------------------------------------

- Net loss $9.2M ($0.14/share) vs $7.6M ($0.12/share) in Q2 2025; R&D $2.1M, G&A $1.8M.
- FDA alignment on Phase 3 trial design for belapectin in MASH cirrhosis; protocol submission expected 3Q 2026.
- Chairman Richard Uihlein converted $105.8M debt (principal $91M + interest $14.8M) into 34.4M shares, effective July 31, 2026.
- Cash $13.2M at June 30, 2026; $10M line of credit available; cash runway through June 2027.
- NAVIGATE trial data published in Hepatology and Gastro Hep Advances; EASL presentations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133416/000114036126032946/0001140361-26-032946-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133416/000114036126032946/ef20080011_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-032946

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer